Carbon Ion Radiation Therapy for Unresectable Sacral Chordoma: An Analysis of 188 Cases

Imai, Reiko; Kamada, Tadashi; Araki, Nobuhito; Abe, Satoshi; Iwamoto, Yukihide; Ozaki, Toshifumi; Kanehira, Chihiro; Kaya, Mitsunori; Takahashi, Kazuhisa; Chuman, Hirokazu; Tsujii, Hirohiko; Tsuneyoshi, Masazumi; Nishida, Yoshihiro; Hiraga, Hiroaki; Hiruma, Toru; Machinami, Rikuo; Matsumine, Akihiko; Matsumoto, Seiichi; Morioka, Hideo; Yamaguchi, Takehiko; Yonemoto, Tsukasa

doi:10.1016/j.ijrobp.2016.02.012

Cited by 135 publications

(147 citation statements)

References 21 publications

Supporting

Mentioning

132

Contrasting

Order By: Relevance

“…Proton or carbon ion RT might become an alternative therapy for unresectable chordoma in the future. 20,35,36 We speculate that a reduced ADC during follow-up after RT might predict early recurrence.…”

Section: Discussionmentioning

confidence: 92%

Role of the Apparent Diffusion Coefficient as a Predictor of Tumor Progression in Patients with Chordoma

Sasaki

Moritani

Belay³

et al. 2018

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 92%

Role of the Apparent Diffusion Coefficient as a Predictor of Tumor Progression in Patients with Chordoma

Sasaki

Moritani

Belay³

et al. 2018

AJNR Am J Neuroradiol

View full text Add to dashboard Cite

show abstract

“…For unresectable sacral chordomas, the NIRS experience of 188 patients with CIRT achieved 77% and 81% 5-year local control and overall survival, respectively, while maintaining 97% ambulation in surviving patients. Grade 3 peripheral nerve toxicity was seen in six patients, and grade 4 skin toxicity in two patients [114]. For unresectable non-skull base chondrosarcomas, the NIRS experience of 75 patients with CIRT demonstrated 55% and 57% 5-year local control and overall survival, with four patients reported as having experienced grade 3 or 4 skin/soft tissue late adverse effects [115].…”

Section: Clinical Experiences With Cirtmentioning

confidence: 99%

Carbon Ion Radiotherapy: A Review of Clinical Experiences and Preclinical Research, with an Emphasis on DNA Damage/Repair

Mohamad

Sishc

Saha

et al. 2017

Cancers

142

130

View full text Add to dashboard Cite

Compared to conventional photon-based external beam radiation (PhXRT), carbon ion radiotherapy (CIRT) has superior dose distribution, higher linear energy transfer (LET), and a higher relative biological effectiveness (RBE). This enhanced RBE is driven by a unique DNA damage signature characterized by clustered lesions that overwhelm the DNA repair capacity of malignant cells. These physical and radiobiological characteristics imbue heavy ions with potent tumoricidal capacity, while having the potential for simultaneously maximally sparing normal tissues. Thus, CIRT could potentially be used to treat some of the most difficult to treat tumors, including those that are hypoxic, radio-resistant, or deep-seated. Clinical data, mostly from Japan and Germany, are promising, with favorable oncologic outcomes and acceptable toxicity. In this manuscript, we review the physical and biological rationales for CIRT, with an emphasis on DNA damage and repair, as well as providing a comprehensive overview of the translational and clinical data using CIRT.

show abstract

“…Proton therapy makes the best use of this physical advantage for application in adjuvant and neoadjuvant RT in STS of the extremities, as it allows for an increase in irradiated doses and decreases in the incidences of late morbidities associated with RT, such as bone fractures . Carbon ion beams have higher biological effectiveness than proton beams do, and CIRT has been used as definitive RT for sarcomas . We reviewed cases with localized unresectable STSs treated with CIRT at a single institute and evaluated the effectiveness and safety of the treatment.…”

Section: Introductionmentioning

confidence: 99%

Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma

2018

Self Cite

View full text Add to dashboard Cite

Carbon ion radiotherapy is known for its high‐precision dose distribution and high biological effectiveness. We evaluated the results of carbon ion radiotherapy in 128 patients with unresectable localized axial soft tissue sarcoma at a single institution. The patients’ median age was 54 years, and the median follow‐up period was 49.4 (range 6.4‐146.4) months. The median tumor volume was 356 cm3. The 5‐year local control, overall survival, and disease‐free survival rates were 65%, 46%, and 39%, respectively. In the univariate analysis, tumor volume, local control, and incidences of metastases were significantly related to overall survival. In the multivariate analysis, tumor volume and local control were significantly related to overall survival. We did not find any factors related to local control. Five patients required surgical intervention because of adverse events in the bones. Carbon ion radiotherapy may be a treatment option for unresectable axial soft tissue sarcoma.

show abstract

Carbon Ion Radiation Therapy for Unresectable Sacral Chordoma: An Analysis of 188 Cases

Cited by 135 publications

References 21 publications

Role of the Apparent Diffusion Coefficient as a Predictor of Tumor Progression in Patients with Chordoma

Role of the Apparent Diffusion Coefficient as a Predictor of Tumor Progression in Patients with Chordoma

Carbon Ion Radiotherapy: A Review of Clinical Experiences and Preclinical Research, with an Emphasis on DNA Damage/Repair

Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma

Contact Info

Product

Resources

About